Vivoryon Therapeutics (VVY) investor relations material

Executive summary

• Advanced term sheet negotiations and ongoing discussions for licensing and investment in varoglutamstat for kidney disease, with increased external interest and independent assessment by a specialist kidney-focused investor.

• Compelling clinical and preclinical data for varoglutamstat in diabetic kidney disease, with a differentiated mechanism of action targeting inflammation, fibrosis, and endothelial function, and evidence of improved and stabilized kidney function.

• Focus shifted from Alzheimer's disease to kidney disorders after positive Phase 2 data, with plans to advance to Phase 2b in DKD.

• Large unmet need in diabetic kidney disease, with millions of patients in the US and EU and blockbuster sales potential confirmed.

• Key findings and new mechanistic data presented at major international nephrology conferences, reinforcing the drug's potential.

Financial highlights

• No revenue reported for H1 2026 or H1 2025.

• Research and development expenses for H1 2026 were EUR 1.7 million, down from EUR 2.8 million in H1 2025.

• General and administrative expenses decreased to EUR 1.7 million from EUR 2.8 million year-over-year.

• Net loss for H1 2026 narrowed to EUR 3.4 million from EUR 5.5 million year-over-year.

• Cash and cash equivalents stood at EUR 2.4 million as of June 30, 2026, down from EUR 5.6 million at year-end 2025.

Outlook and guidance

• Cash runway is expected to extend into Q4 2026, excluding potential proceeds from standby equity agreements, but future viability depends on securing additional funding or partnerships.

• Plans to initiate a dedicated Phase 2b study in advanced kidney disease, pending funding.

• Clinical trial material and protocol are ready, with scientific advice received and no shelf life issues anticipated.